title: Resveratrol Inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells.
abstract: Respiratory syncytial virus (RSV) is the most common pathogen responsible for lower respiratory diseases in children. So far, there is no effective treatment or preventative vaccine available for RSV infection, although ribavirin and dexamethasone are commonly prescribed. Resveratrol has been shown to inhibit the replication of several other viruses, thus the effect of resveratrol on RSV-induced inflammatory mediators in 9HTEo cell cultures was evaluated, and possible mechanisms of action were explored and compared with dexamethasone and ribavirin. Incubation with resveratrol resulted in decreased IL-6 production and partial inhibition of RSV replication. Resveratrol treatment also inhibited virus-induced TIR-domain-containing adapter-inducing interferon-β (TRIF) and TANK binding kinase 1 (TBK1) protein expression. These data demonstrate the ability of resveratrol to inhibit cytokine production by RSV in airway epithelial cells, indicating that it might be a therapeutic agent with both anti-inflammatory and antiviral potential for the treatment of RSV infection.
authors.affiliation: Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing, 400014, People's Republic of China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Xie
authors.forename: Na
authors.initials: N
authors.lastname: Zang
authors.forename: Si-min
authors.initials: SM
authors.lastname: Li
authors.forename: Li-jia
authors.initials: LJ
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Deng
authors.forename: Yun
authors.initials: Y
authors.lastname: He
authors.forename: Xi-qiang
authors.initials: XQ
authors.lastname: Yang
authors.forename: En-mei
authors.initials: EM
authors.lastname: Liu
mesh_terms: D033942:Adaptor Proteins, Vesicular Transport / Q000096:biosynthesis*; D000998:Antiviral Agents / Q000494:pharmacology; D002460:Cell Line; D003907:Dexamethasone / Q000494:pharmacology; D015536:Down-Regulation; D004847:Epithelial Cells / Q000276:immunology / Q000821:virology; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis*; D016209:Interleukin-8 / Q000096:biosynthesis; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis; D020545:Respiratory Mucosa / Q000378:metabolism / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D012137:Respiratory System / Q000378:metabolism / Q000821:virology; D000077185:Resveratrol; D012254:Ribavirin / Q000494:pharmacology; D013267:Stilbenes / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D033942:Adaptor Proteins, Vesicular Transport; D000998:Antiviral Agents; D015850:Interleukin-6; D016209:Interleukin-8; D013267:Stilbenes; C470409:TICAM1 protein, human; D012254:Ribavirin; D003907:Dexamethasone; D017346:Protein Serine-Threonine Kinases; C403191:TBK1 protein, human; D000077185:Resveratrol